Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT03193424 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

NCT NCT03193424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03193424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
December 30, 2019
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal squamous carcinoma